ValuEngine Downgrades Spark Therapeutics (ONCE) to Strong Sell

ValuEngine downgraded shares of Spark Therapeutics (NASDAQ:ONCE) from a sell rating to a strong sell rating in a research report report published on Friday.

Other analysts have also recently issued research reports about the stock. Wedbush raised shares of Spark Therapeutics from an underperform rating to a neutral rating and reduced their target price for the company from $65.00 to $50.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. SunTrust Banks increased their price target on shares of Spark Therapeutics to $113.00 and gave the company a buy rating in a research note on Thursday, January 4th. BMO Capital Markets increased their price target on shares of Spark Therapeutics from $64.00 to $66.00 and gave the company an outperform rating in a research note on Thursday, January 25th. Leerink Swann lowered shares of Spark Therapeutics from an outperform rating to a market perform rating and set a $49.00 price target on the stock. in a research note on Tuesday, December 12th. Finally, Raymond James Financial reiterated a buy rating on shares of Spark Therapeutics in a research note on Tuesday, December 19th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seventeen have given a buy rating to the stock. Spark Therapeutics currently has an average rating of Buy and an average price target of $75.18.

Shares of Spark Therapeutics (ONCE) opened at $54.83 on Friday. The firm has a market cap of $2,030.00, a P/E ratio of -7.62 and a beta of 3.02. Spark Therapeutics has a 1-year low of $41.06 and a 1-year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same period last year, the business earned ($1.07) EPS. research analysts predict that Spark Therapeutics will post -7.55 earnings per share for the current fiscal year.

In other news, CFO Stephen W. Webster sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the transaction, the chief financial officer now directly owns 12,500 shares in the company, valued at $876,750. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the transaction, the insider now owns 215,000 shares in the company, valued at $15,333,800. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,827 shares of company stock worth $3,118,519. Insiders own 7.30% of the company’s stock.

A number of large investors have recently bought and sold shares of ONCE. Gilder Gagnon Howe & Co. LLC purchased a new position in Spark Therapeutics in the 4th quarter valued at $28,188,000. Janus Henderson Group PLC purchased a new position in Spark Therapeutics in the 2nd quarter valued at $30,848,000. Orbimed Advisors LLC purchased a new position in Spark Therapeutics in the 3rd quarter valued at $38,340,000. Rockefeller Financial Services Inc. grew its position in Spark Therapeutics by 27,905.0% in the 4th quarter. Rockefeller Financial Services Inc. now owns 353,983 shares of the biotechnology company’s stock valued at $18,202,000 after buying an additional 352,719 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in Spark Therapeutics in the 3rd quarter valued at $27,239,000. Hedge funds and other institutional investors own 94.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “ValuEngine Downgrades Spark Therapeutics (ONCE) to Strong Sell” was first posted by Stock Observer and is the property of of Stock Observer. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.thestockobserver.com/2018/02/06/valuengine-downgrades-spark-therapeutics-once-to-strong-sell.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply